HF
VYNE icon

HRT Financial’s VYNE Therapeutics VYNE Stock Holding History

HRT Financial’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16K Buy
+27,569
New +$16.1K ﹤0.01% 3594
2025
Q3 		– Sell
-42,037
Closed -$69K – 3761
2025
Q2 		$69K Buy
42,037
+15,795
+60% +$20.5K ﹤0.01% 2266
2025
Q1 		$41K Buy
+26,242
New +$64.6K ﹤0.01% 2253
2024
Q1 		– Sell
-10,043
Closed -$23K – 3177
2023
Q4 		$23K Buy
+10,043
New +$31.3K ﹤0.01% 2028
2023
Q2 		– Sell
-10,304
Closed -$31K – 3367
2023
Q1 		$31K Buy
+10,304
New +$37K ﹤0.01% 2156
2022
Q2 		– Sell
-909
Closed -$10K – 3814
2022
Q1 		$10K Buy
+909
New +$10.8K ﹤0.01% 2899
2021
Q4 		– Sell
-4,334
Closed -$108K – 4177
2021
Q3 		$108K Sell
4,334
-1,462
-25% -$56.7K ﹤0.01% 2879
2021
Q2 		$366K Buy
+5,796
New +$459K ﹤0.01% 2019
2021
Q1 		– Sell
-140
Closed -$15K – 3203
2020
Q4 		$15K Buy
+140
New +$17.6K ﹤0.01% 1751

Other funds holding VYNE

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
TC
T3 Companies New York $76.8M AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

HRT Financial's VYNE Position: Q1 2026 in Review

HRT Financial opened a new position in VYNE Therapeutics (VYNE) in Q1 2026: 27,569 shares worth $16K. The stake represents ﹤0.01% of the portfolio and ranks #3594 among its holdings. This is a return to the name: HRT Financial previously reported a position in VYNE as recently as Q2 2025.

HRT Financial first reported a position in VYNE in Q4 2020 and has held it in 9 quarters since. The position peaked at $366K in Q2 2021. 45 funds tracked by Wall St. Rank hold VYNE as of Q1 2026.

  • HRT Financial held 27,569 shares of VYNE Therapeutics worth $16K as of Q1 2026.
  • VYNE Therapeutics was a new HRT Financial position in Q1 2026.
  • VYNE Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #3594 holding.
  • HRT Financial first reported a position in VYNE Therapeutics in Q4 2020 and has held it in 9 quarters since.
  • HRT Financial's VYNE Therapeutics position peaked at $366K in Q2 2021.
  • 45 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.